🏛️ Verified NIH Record • Updated 2026-07-01
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer (NCT02711553)
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
Who can join: Review the eligibility criteria below.
Location: The University of Arizona Cancer Center — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (82 Sites)
Showing the first 25 of 82 sites.
- The University of Arizona Cancer Center — Tucson, Arizona
- UCSF Medical Center at Mission Bay — San Francisco, California
- Georgetown University Medical Center — Washington D.C., District of Columbia
- University of Florida School of Medicine — Gainesville, Florida
- Karmanos Cancer Institute — Detroit, Michigan
- Washington University Medical School — City of Saint Peters, Missouri
- Washington University Medical School — Creve Coeur, Missouri
- Washington University Medical School — St Louis, Missouri
- Washington University Medical School — St Louis, Missouri
- Thomas Jefferson University — Philadelphia, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Florida Cancer Specialists — Nashville, Tennessee
- Tennessee Oncology PLLC — Nashville, Tennessee
- Alexander Fleming — CABA, BS
- Hospital de Gastroenterologia Udaondo — Capital Federal, Buenos Aires
- Fundacion Ars Medica — San Salvador de Jujuy, Jujuy Province
- Clinica Viedma — Viedma, Río Negro Province
- Centro Medico San Roque — San Miguel de Tucumán, Tucumán Province
- Fundacion Favaloro — Ciudad de Buenos Aires,
- Fundación CORI para la Investigación y Prevención del Cáncer — La Rioja,
- Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan — San Juan,
- Calvary Mater Newcastle — Waratah, New South Wales
- Royal Adelaide Hospital — Adelaide, South Australia
- Austin Health — Heidelberg, Victoria
- Landesklinikum Wr. Neustadt — Wiener Neustadt, Lower Austria
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Biliary Tract Cancer
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers — Pittsburgh, Pennsylvania
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) — Birmingham, Alabama
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) — Mobile, Alabama
- XmAb20717 in Advanced Biliary Tract Cancers — Philadelphia, Pennsylvania
- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) — Phoenix, Arizona
Explore by condition: All Biliary Tract Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.